FOLD — AMICUS THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1178879 ·
Last close
$14.49
Market Cap
$4.55B
52W High
$14.50
52W Low
$14.32
ADV30
3,178,653
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 185,212,000 | 158,665,000 | 15,946,000 | 1,690,000 | 949,870,000 | 214,010,000 | 675,629,000 |
| Sep 2025 | 169,061,000 | 149,594,000 | 34,269,000 | 17,306,000 | 868,811,000 | 190,553,000 | 638,387,000 |
| Jun 2025 | 154,688,000 | 139,471,000 | -7,772,000 | -24,420,000 | 815,303,000 | 158,702,000 | 610,999,000 |
| Mar 2025 | 125,249,000 | 113,551,000 | -7,952,000 | -21,686,000 | 789,839,000 | 181,657,000 | 596,281,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$33,145,000
Investing CF
$-46,432,000
Financing CF
$610,000
CapEx
$-3,296,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.11
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,767,290,000
Inventory
$228,819,000
Receivables
$115,307,000
ST Investments
$79,526,000
EBIT TTM
$46,350,000
Pretax Income TTM
$191,000
Interest Exp TTM
$46,159,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$634,209,984
EBITDA
$41,951,000
Free Cash Flow
$47,844,500
Enterprise Value
$4,698,697,216
Total Cash
$293,536,000
Total Debt
$442,363,008
Shares Out
314,000,712
Trailing EPS
$-0.09
Book Value
$0.88
ROE
-11.6%
ROA
2.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 634,210,000 | 34,491,000 | -27,110,000 | 949,870,000 | 675,629,000 | — | 33,145,000 |
| Dec 2024 | 528,295,000 | 34,064,000 | -56,106,000 | 785,033,000 | 590,988,000 | — | -33,891,000 |
| Dec 2023 | 399,356,000 | -73,494,000 | -151,584,000 | 777,880,000 | 617,706,000 | — | -69,091,000 |
| Dec 2022 | 329,233,000 | -204,426,000 | -236,568,000 | 724,167,000 | 601,120,000 | — | -166,575,000 |
TTM Snapshot
Revenues TTM
$406,254,000
NetIncome TTM
$-111,886,000
OpCashFlow TTM
$0
Assets (Latest)
$785,033,000
Forward EPS
$0.96
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GIKLY | Grifols SA | $4.48B | $5.30 | — |
| INDV | Indivior Pharmaceuticals, Inc. | $4.47B | $37.81 | — |
| GIFLF | Grifols SA | $4.70B | $11.12 | — |
| LGND | LIGAND PHARMACEUTICALS INC | $4.72B | $235.33 | — |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $4.75B | $86.82 | — |
News headlines (Yahoo Finance, 1h cache)
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised
2026-05-05 17:17 · Yahoo
BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says
2026-05-05 15:13 · Yahoo
BioMarin acquires Amicus Therapeutics for $4.8bn
2026-04-28 09:51 · Yahoo
CIBRA Capital Buys Stake in Allied Gold Stock
2026-04-27 18:42 · Yahoo
BioMarin Completes Acquisition of Amicus Therapeutics
2026-04-27 12:44 · Yahoo
CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)
2026-04-25 15:33 · Yahoo
Here is Why BioMarin (BMRN) is Projected to Rally
2026-03-31 07:18 · Yahoo
Assessing Amicus Therapeutics (FOLD) Valuation After A Strong 71% One Year Total Return
2026-03-29 17:03 · Yahoo
Why Is Adma Biologics (ADMA) Down 45.4% Since Last Earnings Report?
2026-03-27 15:30 · Yahoo
Tarsus Pharmaceuticals Stock Earns Upgrade To RS Rating
2026-03-26 17:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.